Literature DB >> 19342702

Body fat content and testosterone pharmacokinetics determine gonadotropin suppression after intramuscular injections of testosterone preparations in normal men.

Britta Kornmann1, Eberhard Nieschlag, Michael Zitzmann, Jörg Gromoll, Manuela Simoni, Sigrid von Eckardstein.   

Abstract

Interindividual differences in gonadotropin suppression achieved by short- and long-acting intramuscular testosterone (T) preparations were studied to detect factors hindering complete suppression of gonadotropins as the prerequisites for effective male contraception. Forty healthy men received a single injection of T propionate; 4 weeks later they received 2 injections of 1000 mg of T undecanoate (TU) given 6 weeks apart. Following TU, declines of luteinizing hormone (LH) and follicle-stimulating hormone (FSH) levels were consistent in 17.5% and almost absent in 25% of men. Men showing the most rapid and consistent declines in LH and FSH levels received a slightly higher dose per body weight of TU (13.1 +/- 0.6 vs 11.3 +/- 0.6 mg/kg; P = NS) and reached higher maximal concentrations of total T (40 +/- 4.8 vs 18.4 +/- 2.4 nmol/L; P < .001) and free T as well as estradiol. Men with high fat mass (mean +/- SEM, 10.3 +/- 1.5 vs 23.2 +/- 6.4 kg) had a delayed increase in T levels and an impaired relative decline in LH (12 +/- 2% vs 53 +/- 10%) and FSH (17 +/- 6%. vs 70 +/- 25%) levels within the first 2 weeks after the first TU injection. We conclude that overweight reduces the chance of rapid and profound gonadotropin suppression during treatment with TU. Body weight needs to be considered to avoid failure of hormonal male contraception.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19342702     DOI: 10.2164/jandrol.108.006296

Source DB:  PubMed          Journal:  J Androl        ISSN: 0196-3635


  5 in total

1.  On the pill.

Authors:  Ellen Friedrichs
Journal:  Nat Med       Date:  2010-05       Impact factor: 53.440

Review 2.  Occurrence of pulmonary oil microembolism (POME) with intramuscular testosterone undecanoate injection: literature review.

Authors:  Jarren A Adam; Alexander W Pastuszak; Michael B Christensen; Rachel Spencer; Ashlynn Sandberg; James M Hotaling; Larry I Lipshultz
Journal:  Int J Impot Res       Date:  2022-05-24       Impact factor: 2.896

3.  Hormonal, chemical and thermal inhibition of spermatogenesis: contribution of French teams to international data with the aim of developing male contraception in France.

Authors:  Jean-Claude Soufir
Journal:  Basic Clin Androl       Date:  2017-01-13

Review 4.  Testosterone Use in Adolescent Males: Current Practice and Unmet Needs.

Authors:  Maria Vogiatzi; James P Tursi; Jonathan S Jaffe; Sue Hobson; Alan D Rogol
Journal:  J Endocr Soc       Date:  2020-10-30

5.  Optimal injection interval for testosterone undecanoate treatment of hypogonadal and transgender men.

Authors:  Nandini Shankara Narayana; Lam P Ly; Veena Jayadev; Carolyn Fennell; Sasha Savkovic; Ann J Conway; David J Handelsman
Journal:  Endocr Connect       Date:  2021-07-14       Impact factor: 3.335

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.